Apolipoprotein E ε4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration
about
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapyValidation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed casesNeuropathology of non-Alzheimer degenerative disordersThe potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's diseaseChronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank.Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study.TDP-43 is a key player in the clinical features associated with Alzheimer's diseasePredicting functional decline in behavioural variant frontotemporal dementia.Quantitative neuropathological assessment to investigate cerebral multi-morbidity.APOE ε4 influences β-amyloid deposition in primary progressive aphasia and speech apraxia.Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia.Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degenerationApolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortexAmyloid in dementia associated with familial FTLD: not an innocent bystander.Digital pathology and image analysis for robust high-throughput quantitative assessment of Alzheimer disease neuropathologic changesTau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansionSequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementiaAn evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology.Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities.Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease.Patterns of atrophy differ among specific subtypes of mild cognitive impairment.Beta-amyloid burden is not associated with rates of brain atrophy.Quantitative neurofibrillary tangle density and brain volumetric MRI analyses in Alzheimer's disease presenting as logopenic progressive aphasia.Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype.Staging TDP-43 pathology in Alzheimer's disease.Progranulin-associated PiB-negative logopenic primary progressive aphasia.Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review.The Differential Effects of Alzheimer's Disease and Lewy Body Pathology on Cognitive Performance: a Meta-analysis.Pathology of Neurodegenerative Diseases.Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice.One hundred years of Alzheimer's disease and the neglected second lesson of Aloïs Alzheimer on multicausality in dementia.Multiple system atrophy and apolipoprotein E.Neuropathology of Dementia in Parkinson's DiseaseProgressive Supranuclear Palsy and Corticobasal Degeneration
P2860
Q24604376-BE562D9C-6D9E-4A96-A391-B49D8773A0BFQ24653609-68E51F04-48DC-4152-A8F1-342677EA6D15Q24657571-277EF624-7A68-41BF-AFCB-C6CC34C51219Q26853347-105BCF65-C46C-4AB3-BF1D-329751FD25BDQ33457735-F79ED3B0-C96E-4ABD-B9DB-CD757063D960Q33656306-3D837BE3-4E62-4447-9BAD-783B61EC1881Q34232167-A971012E-E728-4660-89BB-424AB920ABCFQ34538903-6306C596-798A-47C4-BEC2-D887BC8449AFQ34584768-F236C44B-D938-4990-A6A8-E309856842F8Q34622674-620A29CD-8760-4A9A-90AC-EE21A837AD78Q35234807-58AB1AAF-CEF1-48F0-9F37-BB7AB425F053Q35630371-5E258AF7-808E-4926-B9EB-3BE6EDE76AB1Q36115080-5A894E60-E680-48F4-B2ED-0ACD767E59EBQ36327682-EF83A0D5-F743-43FF-88B4-E082782BAA43Q36438010-AF26142C-2A74-4083-AAD9-4A613744D154Q36553164-37675AC9-A63B-4CBF-9E59-BF9CA50A4BC4Q36631666-24CF37E5-E23C-4E76-8D47-99A38EB4ECF4Q36758618-28F371CE-DD70-439D-A39A-09041D473794Q37060457-E5B78D88-9EB9-4057-8BAF-F6F070B8546BQ37315477-FBAB2A81-A394-4C3B-BDB1-726330366198Q37326509-1895574E-4EC2-4104-9C4C-1A1FC238751CQ37326537-DA63D085-AC44-4511-AA36-D682ED29828AQ37341600-0F74589E-C4E9-4FE7-ADBB-96FD192C807AQ37425165-3BC86194-7DD7-4B6B-9B3C-F48F0D614309Q37621617-0CAC3BAB-39BC-469E-8639-A8F7008B6B75Q37652740-9F339CFC-4910-4F60-B7C5-086FC82016E2Q38154832-B635B894-CE86-485C-9FCD-70AE811819B6Q39017659-35F4AAE8-BD60-48F5-BB6A-DDB26BC5AEDDQ39071493-5EB91E9F-783C-42D4-AB9D-6A6CF7B3C7D2Q39155261-0C453E79-2CD9-43D4-860B-0E7DDED64C65Q46804251-62AB9096-48E8-431E-994B-7062A7959339Q48614261-34036308-9D48-4FD8-A4E7-24733BE38E92Q50016001-C9266EDC-843D-4918-A028-C51FC23627C8Q57306342-FFDE29BA-2F82-4AFE-B7EA-E95E944B1CE8Q57306343-B1CEBBCF-65D8-4C23-A639-26DEE417D55E
P2860
Apolipoprotein E ε4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration
description
im Oktober 2004 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2004
@uk
name
Apolipoprotein E ε4 Is a Deter ...... nd Frontotemporal Degeneration
@en
Apolipoprotein E ε4 Is a Deter ...... nd Frontotemporal Degeneration
@nl
type
label
Apolipoprotein E ε4 Is a Deter ...... nd Frontotemporal Degeneration
@en
Apolipoprotein E ε4 Is a Deter ...... nd Frontotemporal Degeneration
@nl
prefLabel
Apolipoprotein E ε4 Is a Deter ...... nd Frontotemporal Degeneration
@en
Apolipoprotein E ε4 Is a Deter ...... nd Frontotemporal Degeneration
@nl
P2093
P1433
P1476
Apolipoprotein E ε4 Is a Deter ...... nd Frontotemporal Degeneration
@en
P2093
Hilary Watt
Keith A. Josephs
Natalie Cookson
Yoshio Tsuboi
P356
10.1001/ARCHNEUR.61.10.1579
P577
2004-10-01T00:00:00Z